Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Shareholder Meeting (May 2005)
17 slides from Neuren Pharmaceuticals's shareholder meeting presentation, May 30, 2005
Slide 1: Neuren Pharmaceuticals AGM cover letter to ASX
Neuren Pharmaceuticals Ltd Level 3, 2-6 Park Avenue, Grafton Auckland, New Zealand office: +64 9 367 7167 fax: +64 9 367 7186 enquiry@neurenpharma.com www.neurenpharma.com 30 May 2005 The Company Announcements Office Australian Stock Exchange Limited BY E-LODGEMENT Dear Sirs NEUREN PHARMACEUTICALS L
Slide 2: Pharmaceuticals May 2005 Update
Pharmaceuticals May 2005 Update
Slide 3: Overview
Overview • On track for Phase 2 and Phase 1 •Progress made on all Milestones • Partnerships Strengthened • US Army • Metabolic • Board and Management Strengthened 2
Slide 4: Recap…
Recap… A unique pharmaceutical development company targeting: – Neuroprotection – Metabolism and Cancer • Large and Growing Markets • Recognised Significant Unmet Medical Need 3
Slide 5: Global Markets with Unmet Needs
Global Markets with Unmet Needs Indication Cases per Market Size Effective Year (USA) US$ Treatment Neuroprotection On-pump heart surgery 400,000 $2.0b N Traumatic Brain Injury 1,000,000 $1.0b N Stroke 800,000 $3.5b N Parkinson’s Disease 3,000,000 $2.0b Y/N Alzheimer’s Disease 4,500,000 $2.5b Y/N Mu
Slide 6: Deep Pipeline of Products
Deep Pipeline of Products y n ac ¾ 5 Families of Compounds Ilb tio . lP a ox fic Il uc I se d lT Ef se se ea od ha ha ica ha Ma ical dL n Pr ery ¾ 72 Patents tio lP lP lin lin ate ial ca ov ula ca e-C ca e-C ter ini sc lid ini rm ini Pr Cl Di Va Pr Cl Cl Fo • Glypromate® • NNZ-2566 (acute/sub-acute)
Slide 7: Significant Partnerships in Place
Significant Partnerships in Place Indication Partner CABG UCL/Duke University TBI Walter Reed US Army Stroke University of Houston Metabolism Pfizer Inc., Metabolic Pharmaceuticals Ltd Nerve Repair Metabolic Pharmaceuticals Ltd Discovery The Liggins Institute, IMB Com ¾ Drug Co-Development ¾ Out-Lic
Slide 8: Clinical Development – Current Status
Clinical Development – Current Status • Glypromate – Phase 2 on target – Prof. Stan Newman added to Team • UCL World Expert on Cognitive Decline in Open Heart – Pre-IND meeting held • NNZ 2566 Acute – Phase 1 on target – Manufacturing Finalised and Cost Effective – Tox Study Supplier Selected 7
Slide 9: US Army Stage 2
US Army Stage 2 Walter Reed • Second Lead candidate ..NNZ2566 • TBI Stage 1 Results Strong Effectiveness – Neuren Science Confirmed in US market • US Army 2nd Stage – Recent New Results improve dose effectiveness • Additional work with US army planned • “Goal… advanced drug for brain injury” 8
Slide 10: Metabolic Deal NRP Class of Drugs
Metabolic Deal NRP Class of Drugs • Novel Actions… Nerve Regeneration • NRP underwent Due Diligence – Incl overseas and independent validation • Faster Development at Less Costs – MBP 2:1 • Government Grant A$585,000 • Utilise MBP Peptide Chemistry Skills 9
Slide 11: People…
People… 10
Slide 12: Management Replacements Advisory
Clinical Development Experience Management Replacements • Robyn Murdoch, CDO - ex Pfizer, Roche, Lilly • Dr Mike Bickerdike, Managing Scientist – ex UK Private Biotech • Rob Turnbull , CFO - ex private Biotech , PwC Advisory • Prof. Stan Newman - UCL 11
Slide 13: Board of Directors
Board of Directors • Dr Robin Congreve, PhD (Chairman) – Leading NZ lawyer – Partner in Oceania and Eastern Group • David Clarke, ME, MBA (CEO) – Senior positions in healthcare ,technology and finance – Former CEO, South Auckland Health (4,000 employees, Revenue NZ$500M) • Tom Amos, B.Eng – Director
Slide 14: Investor Value Adding Milestones
Investor Value Adding Milestones ALL ON TARGET: • US army deal, NRP deal • 2566 CMC • Glypromate – Complete Phase IIa in ‘on-pump’ • Glypromate – Commence Phase IIb in ‘on-pump’ • NNZ-2566 – Phase I • NNZ-2566 - Oral • NRP – Lead Candidate Selection, Manufacturing & Pre-clinical • DKP’s / MC’s - Lea
Slide 15: Conclusion…
Conclusion... neuren 14
Slide 16: Key Messages
Key Messages Business is sound and on track: • Lead products on TARGET – Milestones focused on increasing investor value • Utilising Partnerships, including Pfizer & – US Army – Metabolic • Building on the pipeline with multiple product families – Powerful GPE/2566/Oral package – Building value on o
Slide 17: Thank you for Your Support
Pharmaceuticals Thank you for Your Support 16
Neuren Pharmaceuticals — Shareholder Meeting (May 2005) on 6ix